Abstract 337P
Background
To determine the percentage of breast cancers detectable by fused diffusion-weighted imaging (DWI) using unenhanced magnetic resonance imaging (MRI) and abbreviated post-contrast-enhanced MRI.
Methods
Between October 2016 and October 2017, 194 consecutive women (mean age, 54.2 years; age range, 28-82 years) with newly diagnosed unilateral breast cancer who underwent preoperative 3.0 T breast MRI with DWI were evaluated. Both fused DWI and abbreviated MRI images were independently reviewed by two radiologists for the detection of index cancer (which showed the most suspicious findings in both breasts), location, lesion conspicuity, lesion type, and lesion size. Moreover, the relationship between cancer detection and histopathological results of surgical specimens were evaluated.
Results
Index cancer detection rates were comparable between fused DWI and abbreviated MRI (radiologist 1: 174/194 [89.7%] vs. 184/194 [94.8%], respectively, P = 0.057; radiologist 2: 174/194 [89.7%] vs. 183/194 [94.3%], respectively, P = 0.092). In both radiologists, abbreviated MRI showed a significantly higher lesion conspicuity than fused DWI (radiologist 1: 9.37 ± 2.24 vs. 8.78 ± 3.03, P < 0.001; radiologist 2: 9.16 ± 2.32 vs. 8.39 ± 2.93, P < 0.001). The κ value for the interobserver agreement of index cancer detection was 0.67 on fused DWI and 0.85 on abbreviated MRI. For lesion conspicuity, the intraclass correlation coefficients were 0.72 and 0.82 on fused DWI and abbreviated MRI, respectively. Among the histopathological factors, tumor invasiveness was associated with cancer detection on both fused DWI (P = 0.011) and abbreviated MRI (P = 0.004, radiologist 1), lymphovascular invasion was associated with cancer detection on abbreviated MRI (P = 0.032, radiologist 1), and necrosis was associated with cancer detection on fused DWI (P = 0.031, radiologist 2).
Conclusions
Index cancer detection was comparable between fused DWI and abbreviated MRI, although abbreviated MRI showed a significantly better lesion conspicuity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
303P - Differential prognostic role of PDGFRA alterations in breast cancer subtypes
Presenter: Panagiotis Vlachostergios
Session: Poster session 02
304P - Generalizability of 313-SNP PRS for breast cancer risk in non-European ancestries
Presenter: Helen Shang
Session: Poster session 02
305P - Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
Presenter: Sora Kang
Session: Poster session 02
307P - Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline
Presenter: Xixuan Zhu
Session: Poster session 02
308P - Regression-based deep-learning predicts breast cancer recurrence risk score from pathology slides
Presenter: Omar El Nahhas
Session: Poster session 02
310P - Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay
Presenter: Mitchell Elliott
Session: Poster session 02
311P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on the genetic counselling experience
Presenter: Ranjit Kaur
Session: Poster session 02
312P - Prediction model of breast cancer patient’s neoadjuvant treatment outcome using breast cancer organoids cultured from core needle biopsies
Presenter: Dong Woo Lee
Session: Poster session 02